Title
Management of Relapsed Hairy Cell Leukemia: A Systematic Review of Novel Agents and Targeted Therapies
Document Type
Article
Publication Title
Clinical Lymphoma, Myeloma & Leukemia
Abstract
Hairy cell leukemia (HCL) responds well to purine analogs with an overall median relapse free survival of 11-16 years. Most patients can be retreated with the same or a different purine analog however a subset of patients will become resistant or develop cumulative toxicities. Novel agents such as Vemurafenib (BRAF kinase inhibitor), Bendamustine/Rituximab (BR), Moxetumomab pasudotox (anti CD-22 recombinant immunotoxin) and Ibrutinib have emerging roles in patients with relapsed HCL.
First Page
237
Last Page
238
DOI
https://doi.org/10.1016/j.clml.2021.06.007
Publication Date
Summer 6-24-2021
Recommended Citation
Siddiqui R, Sardar M, Shahzad M, Jose J, Selene I, Shah Z, Qureshi A, Shafqat M, Kashif R, Ahmad M, Mejia-Garcia A, Anwer F. Management of Relapsed Hairy Cell Leukemia: A Systematic Review of Novel Agents and Targeted Therapies. Clin Lymphoma Myeloma Leuk. 2021 Jun 24:S2152-2650(21)00237-8. doi: 10.1016/j.clml.2021.06.007. Epub ahead of print. PMID: 34275772.